A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB
Phase: PHASE3
Conditions: Patch/Plaque Stage Mycosis Fungoides
Sponsor: Medical University of Graz

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 1 of 29 
A multi-center, randomized study on oral 8-methoxypsoralen plus 
UVA with or without maintenance therapy in mycosis fungoides 
EORTC/ISCL stage Ia to IIb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study protocol:  
Version 2.1, February 23, 2018 
Study designation: M-PUVA 2012 
 
Protocol authors:  
Regina Fink-Puches, MD, and Peter Wolf, MD 
 
 
 
Department of Dermatology 
Medical University of Graz 
Auenbruggerplatz 8 
A-8036 Graz, Austria 
TEL +43/316/385-80315 
FAX +43/316-385-12466 
e-mail:peter.wolf@medunigraz.at; regina.fink@medunigraz.at 
http://www.medunigraz.at/bioimmuntherapie 
 
 
Statistics:  
Franz Quehenberger, PhD 
Institute for Medical Informatics, Statistics and Documentation, Medical 
University of Graz, Graz, Austria 
Coordination Centre for Clinical Trials, Medical University of Graz 
Head: Gabriele Pfaffenthaler, MSc 
TEL +43/316/385-72061 
FAX +43/316-385-72030 
e-mail: kks@medunigraz.at 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 2 of 29 
LIST OF CONTENTS 
1. Background and Introduction  
1.1. Prognosis 
1.2. Aetiology and Pathogenesis 
1.3 Treatment 
1.3.1 .PUVA therapy 
1.3.2. Rationale for proposed study 
2. Objectives of the trial 
2.1. General objectives 
3. End points 
3.1. Primary end point 
3.2. Secondary endpoints 
4. Patient selection criteria 
4.1. Inclusion criteria 
4.2. Exclusion criteria 
5. PUVA treatment/Follow-up 
6. Definition of response 
7. Definition of recurrence 
8. Adverse Events 
Known Side effects of PUVA Therapy 
8.1. Dermatologic side effects 
8.2. Gastrointestinal side effects 
8.3. Central Nervous System Side Effects 
8.4. Other Adverse effects 
9. Premature Termination 
10. Monitoring 
11. Data protection 
12. Clinical evaluation and laboratory tests 
12.1. Before treatment  
12.2. During treatment and in the follow-up period 
13. Statistics 
13.1. Study design 
13.2. Sample size calculations and study duration 
13.3. Randomization procedure 
14. Ethical and Legal Aspects 
15. Signatures 
 
16. References 
17. Appendix (Tables and Figures) 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 3 of 29 
1. Background and Introduction  
 
Mycosis Fungoides (MF) represents the most common type of cutaneous T-cell lymphoma (CTCL), 
accounting for about two thirds of all CTCLs and for almost 50% of all primary cutaneous lymphomas 
[WILLEMZE]. It is characterized by the progressive evolution of erythematous patches, plaques and 
tumours over years. 
 
1.1. Prognosis  
 
Most prognostic factors in MF include type and extent of skin involvement and presence or absence of 
extracutaneous disease, which determine clinical stage (Appendix: Table 1).  Recent findings suggest that 
patient’s life expectancy is not adversely affected in stage I A (limited patch, papules and/or plaques 
covering <10% of the skin surface), while patients diagnosed with tumor disease or erythroderma (stages 
IIB-IVB) have a worse overall outcome, with median survival of 4 to 5 years [WILLEMZE]. 
 
1.2. Aetiology and Pathogenesis 
 
Although the aetiology of MF is unknown, important insights have been gained in the pathogenesis and 
immunological perturbations that are associated with this disease. Whereas the disease is characterized by 
infiltration and proliferation of T helper lymphocytes (mainly CD4+) in the skin, CDla+ Langerhans cells 
are thought to be involved in its pathogenesis as well. Furthermore there is evidence, that an abnormal 
cytokine expression in MF might be responsible for tumor progression. Moreover, cytokine loops might 
explain phenomena like the epidermotropism of malignant cells and/or the depression of the anti-tumor 
immune response [HWANG].  
 
1.3. Treatment  
 
There is no curative therapy for MF and the aim of treatment is to induce complete remissions of disease 
and to prolong disease free and finally overall survival while maintaining the patient’s quality of life. 
There have been a large number of uncontrolled studies in MF with response data but virtually no other 
controlled studies with data on disease free and overall survival. Most comparative studies in MF have 
been based on relatively small numbers of patients, which has also severely limited any statistical 
interpretation.  
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 4 of 29 
1.3.1. PUVA therapy 
 
It is now commonly accepted that early-stage MF should be initially treated with skin-directed therapies. 
More aggressive treatments should be reserved for higher stages or progression [TRAUTINGER]. Skin 
directed therapies include topical corticosteroids, topical chemotherapy, topical bexarotene, radiotherapy 
and phototherapy. The first report of PUVA treatment [psoralen plus ultraviolet (UV) A] in MF was 
published in 1976 [ GILCHREST]. Since then several groups have successfully used PUVA to treat MF 
[ROENIGK, HÖNIGSMANN, DIEDEREN]. Today PUVA therapy is a well-accepted first-line treatment 
option for skin-limited MF, because there is good evidence that it is effective in clearing of skin lesions in 
early stages of the disease. Long-term remissions can be achieved in a certain percentage of patients 
[TRAUTINGER]. However, MF lesions may reappear after a very variable time interval with median 
time to recurrence of 9 to 15 months [WACKERNAGEL]. 
 
The mechanism of action of PUVA in MF is not entirely understood. PUVA selectively 
eliminates T-lymphocyte populations by induction of apoptosis. It causes a functional impairment of 
CDla+ Langerhans cells, which are thought to be involved in the pathogenesis of MF by perpetuating the 
epidermal affinity of infiltrating T cells. It may also act by directly downregulating homing receptors on 
epidermotropic malignant T cells and by interfering with epidermal cytokine production 
[HÖNIGSMANN].  
 
1.3.2. Rationale for proposed study 
 
Maintenance PUVA-therapy might be beneficial in slowing relapse of MF after complete initial 
remission. However, controlled clinical trials concerning PUVA maintenance have not been performed so 
far [QUERFELD, SANCHEZ, POTHIAWALA]. Moreover, no evidence is available on the optimal 
frequency and length of maintenance therapy either [HÖNIGSMANN].  
 
2. Objectives of the trial  
2.1 General objectives:  
To determine whether PUVA maintenance therapy does prolong disease free survival after initial 
complete response. 
 
3. End-points  
3.1. Primary endpoint: 
Comparison of median time to recurrence after complete remission between patients treated with 
maintenance therapy vs. patients without maintenance therapy. 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 5 of 29 
3.2. Secondary endpoints  
- Comparison of time from end of treatment to recurrence on condition that the patient is in complete 
remission at the end of treatment between patients treated with maintenance therapy vs. patients without 
maintenance therapy. 
- Cytokine response in serum and tissue 
 
- Quality of life 
 
- HADS 
 
 
4. Patient selection criteria  
 
4.1. Inclusion Criteria: 
 
• 
Histopathologically documented MF clinical stage IA-IIB (see Table1) confirmed by current or 
previous diagnostic lesion biopsy 
• 
A Karnofsky performance score > 60 (see Table 2)  
• 
Age > 18 years - ≤ 85 
• 
Anti-ds-DNA  (antinuclear antibodies) AND anti-Ro/La antibodies: negative 
• 
 Acceptable organ function defined as follows: 
SGOT (AST) and SGPT (ALT) < 2.5 times the upper limit of normal for the institution 
• 
Creatinine < 2 times the upper limit of normal for the institution  
• 
No evidence of severe cardiac insufficiency  (NYHA grade III-IV)  
• 
Women of child bearing potential must have a negative serum or urine pregnancy test (ß-HCG) 
within seven (7) days prior to randomization  
• 
Absence of any serious intercurrent illness or infection at time of entry into the study that could 
interfere with planned treatment  
• 
Patients must be willing to accept limiting sun exposure on the day receiving PUVA treatment  
• 
Written informed consent  
 
4.2. Exclusion criteria: 
 
• 
Pregnancy and Lactation 
 
• 
Photosensitive diseases such as lupus erythematosus or basal cell nevus syndrome 
 
• 
Skin cancer syndromes such as Xeroderma pigmentosum or basal cell nevus syndrome 
 
• 
PUVA (oral or topical) treatment within the last 3 months 
 
5. PUVA treatment and follow-up 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 6 of 29 
Psoralens are photosensitising agents. Methoxsalen – the most commonly used drug is a psoralen 
derivative that is structurally and pharmacologically related to trioxsalen. For PUVA treatment 8-
methoxypsoralen (8-MOP) will be used. Patients receive a liquid preparation of 8-MOP (10 mg) in soft 
gelatine capsules (Oxsoralen®; Gerot Pharmazeutika GmbH, Vienna, Austria, please refer to the 
Summary of Product Characteristics). The dose of 8-MOP is based on the patient’s weight. The standard 
dose of approximately10 mg per 20 kg body weight will be given 1 h before UVA exposure, according to 
the following table: 
 
Body weight  
(kg) 
8-MOP (Oxsoralen) dose  (10mg = 
1 Cps) 
mg = Cps  
< 30 
10 = 1 
30 - 50 
20 = 2 
51 - 65 
30 = 3 
66 - 80 
40 = 4 
81 - 90 
50 = 5 
91 - 115 
60 = 6 
> 115 
70 = 7 
 
 
The initial (starting) UVA dose after psoralen administration will be applied according to the results of 
skin phototoxicity dose testing.  The minimal phototoxic dose (MPD) will be determined by irradiating 
several skin areas 2 cm in diameter using a Waldmann UVA 800 unit (or similar equipment) with varying 
light exposure doses and determining the exposure dose that produces slight homogenous erythema at 72 
hours.  The following dose series will be applied in MPD phototesting: The standard series is Series 1; 
only if there is no erythema detectable at 72h at any dose in series 1, a second MPD testing with series 2 
will be performed and read again at 72h after test exposure: 
 
UVA dose (J/cm2) series 
Series 1 
0,5 
1 
2 
3 
4 
5 
Series 2 
1,5 
2 
3 
5 
7 
9 
 
 
 
The response in MPD testing will be scored as follows: 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 7 of 29 
 
Erythema: 
-, no erythema; +/- non-homogenous erythema; +, homogenous light erythema; ++, dark erythema; +++, 
erythema and edema; ++++, blistering 
 
Pigmentation: 
-, none; +, slight; ++, moderate; +++, strong; ++++, maximum 
 
The initial dose of UVA administered will be 0.5 (50%) of the MPD.  The dose of UVA will be increased 
weekly by 0-30%, depending on the presence or absence of erythema. Each patient will be treated 2 times 
a week (treatment week days at least 2 days apart, e.g. Monday/Thursday or Tuesday/Friday).  UVA 
radiation will be delivered using a Waldmann PUVA 7001 K box (Waldmann Medizintechnik, Villingen-
Schwenningen, Germany) equipped with Waldmann F85/100 W-PUVA fluorescent bulbs or similar UVA 
irradiations systems.  
 
Dose adjustments will be done at any treatment, according to the erythema response of the skin: 
 
no erythema (-) 
 
regular dose, as scheduled according to protocol (increased by 30% 
once weekly) 
non-homogenous 
erythema 
(i.e. 
erythema at certain body sites) (-/+) 
same dose,  no dose increment 
 
homogenous light erythema (+) 
skip one exposure and reduce dose to previous dose that was well 
tolerated  
dark erythema, edema or blister   
(++ to ++++) 
stop of treatment until remission of skin alterations; reduce dose to 
previous dose that was well tolerated  
 
In addition side effects including nausea and vomiting will be recorded on the Initial Therapy sheet and 
Maintenance Therapy sheet according to the following ratings:  
 
 
 
 
 
Nausea: 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 8 of 29 
none (-) 
 
mild (+) 
loss of appetite without alteration in eating habits 
moderate (++) 
oral intake decreased without significant weight loss, 
dehydration or malnutrition 
severe (+++) 
inadequate oral caloric or fluid intake 
 
Vomiting: 
none (-) 
 
mild (+) 
1 episode in 24 hours 
moderate (++) 
2-5 episodes in 24 hours 
severe (+++) 
> 6 episodes in 24 hours 
 
After 12 weeks of treatment or thereafter at week 16, 20 or 24 (after 24, 32, 40, or 48 PUVA treatments, 
respectively) patients with complete remission will be randomized by a computer generated list for 
treatment allocation into two arms (arm A and B, see below). Patients who haven’t experienced complete 
remission after 24 weeks will discontinue active study participation and will enter an observatory study 
arm. 
 
Patients with complete response will be randomized to receive either PUVA-maintenance therapy (arm 
A) or no maintenance therapy (arm B) (Figure 1) 
 
Arm A: oral 8-MOP+UVA 
  
Patients will be treated with PUVA maintenance therapy at constant single UVA doses (UVA-dose will 
be the same as given in the last treatment session in week 12, 16, 20 or 24 of PUVA therapy). 
Maintenance treatment will be given once a week for one month (4 weeks), every 2 weeks for 2 months 
(8 weeks) and after three months once a month over 6 months (Appendix: Figure 1). After 9 (10, 11, or 
12) months of maintenance therapy (14 treatments) patients will discontinue therapy. If PUVA treatment 
does lead to erythema during maintenance therapy, the dose for the next treatment will be reduced by up 
to 30%.  
 
Patients with recurrence during PUVA maintenance will discontinue the study. After the end of 
maintenance therapy the patients will be followed up every three months in the first year after treatment, 
every 6 months in the second year and once a year from year 3 to 5 or until recurrence of the disease.  
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 9 of 29 
Arm B: control arm – Patients will receive no therapy. Patients are followed up at the same intervals like 
patients in study arm A (Appendix: Table 4). 
 
Observatory patient arm:  
Patients who did not response completely to therapy after a maximum of 24 weeks or 48 PUVA 
treatments and patients with recurrent disease (see section 7) after complete response will enter an 
observatory arm. Treatment of these patients will be entirely in the discretion of the treating physician. 
These patients will have follow-up visit at month 12 after stop of PUVA treatment or at time point of 
recurrence to record patient history and clinical status. 
 
6. Definition of response 
 
The extent of the cutaneous involvement of the disease will be determined before start of PUVA 
treatment and monitored during and after treatment by assessing the modified severity-weighted 
assessment tool (mSWAT) [STEVENS]. mSWAT is an objective, quantitative, severity-weighted method 
to assess the extent of CTCL lesions (Appendix: Table 3).  
Quantitative tool to assess disease burden in CTCL [STEVENS]: 
The body is divided into 12 regions with preassigned %TBSA based on methodology used to assess 
burns. The extent of skin disease is assessed for each region and quantified by using the patient's palm as 
a "ruler" to measure the %TBSA involvement within each region: 
• 
Patient's palm with 4 fingers, excluding the thumb and measured from wrist to 
fingertips, is 1% of TBSA. 
• 
Patient's palm without fingers is 0.5% of TBSA. 
 
mSWAT Score calculation: Sum of %TBSA from all body regions affected by patches X severity-
weighting factor of 1 + Sum of %TBSA from all body regions affected by plaques X severity-weighting 
factor of 2 + Sum of %TBSA from all body regions affected by tumors X severity-weighting factor of 4 
(Appendix: Table 3). 
Specific skin lesions will be differentiated in: 
Patches: flat lesions with a diameter larger than 1cm  
Plaques: elevated/palpable lesions with increased consistency with a diameter larger than 1cm  
Tumors: nodular lesions with the longest diameter larger than 1 cm. 
 
Response will be determined as follows:  
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 10 of 29 
- 
Complete clinical response: Complete clinical disappearance of all cutaneous MF lesions 
compared to baseline mSWAT. (Clinically evident postlesional erythema and/or pigmentation 
will not be considered as persistent disease. It will be recorded but will not affect mSWAT.) If 
there is clinical doubt of complete remission, a diagnostic biopsy should be performed. 
- 
Partial response (PR): more or at least 50% reduction in mSWAT 
- 
Stable disease (SD): less than 50 % reduction (from baseline) and less than 25 % increase of skin 
disease (compared with the smallest mSWAT since treatment started)  
- 
Progressive disease (PD): more than 25 % increase in mSWAT compared with the smallest 
mSWAT since treatment started.  
 
7. Definition of recurrence 
Recurrence will be defined as re-occurrence of cutaneous disease, as determined by mSWAT at any time 
point (Complete remission = 100% clearing of skin disease (mSWAT of 0); recurrence is reappearance of 
skin lesions (mSWAT > 1)) [OLSEN (b)]:. If there is clinical doubt of continuous remission, a biopsy 
should be performed. 
 
8. Adverse Events  
Definitions 
Adverse Event (AE) 
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An 
adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (see note for 
guidance on Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). 
 
Serious Adverse Event (SAE), Serious Adverse Drug Reaction (Serious ADR) 
Any untoward medical occurrence that at any dose: 
• results in death, 
• is life-threatening, 
• requires inpatient hospitalisation or prolongation of existing hospitalisation, 
• results in persistent or significant disability/incapacity, 
or 
• is a congenital anomaly/birth defect 
 
Suspected unexpected serious adverse drug reactions (SUSARs) 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 11 of 29 
Suspected Unexpected Serious Adverse Drug Reactions (SUSARs) are side effects (probably or definitely 
connected with the administration of the investigational product), the nature or severity of which are 
inconsistent with the information available about the product. Information about the trial product 
contained in the SmPC (Summary of medicinal Product Characteristics) should be used to verify if the 
adverse reaction has been previously described. 
 
Safety reporting 
Investigator: 
The investigator is responsible for reporting AEs, SAEs and SUSARs to the sponsor. 
All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs 
that the protocol or other document (e.g. Summary of Product Characteristics) identifies as not needing 
immediate reporting. The immediate reports should be followed promptly by detailed, written reports. 
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the 
trial subjects rather than by the subjects’ names, personal identification numbers, and/or addresses. The 
investigator should also comply with the applicable regulatory requirement(s) related to the reporting of 
unexpected serious adverse drug reactions to the regulatory authority(ies) and the ethics committee. 
Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations 
should be reported to the sponsor according to the reporting requirements and within the time periods 
specified by the sponsor in the protocol. 
For reported deaths, the investigator should supply the sponsor and the ethics committee with any 
additional requested information (e.g., autopsy reports and terminal medical reports). 
 
 
Sponsor: 
The sponsor should keep records of all AEs reported by the investigators. These records should be 
forwarded upon request to the competent authority of the region where the Clinical Trial is performed. 
In case of death or immediate danger of life caused by a SUSAR the competent authorities and Ethics 
Committee(s) concerned should be informed by the sponsor within 7 days after the event becomes known 
to the sponsor. Additional information should be given within further 8 days. 
All other SUSAR (“requires inpatient hospitalisation or prolongation of existing hospitalisation,  results 
in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect) should be 
reported as soon as possible, at latest within 15 days after the event becomes known to the sponsor, to the 
competent authorities and Ethics Committee(s) concerned. 
Information on SUSARs should be forwarded to all other investigators of the same clinical trial by the 
sponsor. Once yearly during the trial, a safety report and a listing of all SUSARs that occurred during the 
trial should be forwarded to the competent authorities and to the Ethics Committees concerned by the 
sponsor. 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 12 of 29 
 
 
Known Side effects of PUVA-Therapy 
8.1 Dermatologic Effects  
Phototoxic reactions including severe edema, erythema, painful acral blistering, burning, and peeling of 
skin may occur with methoxsalen and conventional UV light. In addition, PUVA therapy has produced 
marked hyperpigmentation and, with high cumulative doses, photoageing of skin.  
 
8.2 Phototoxic reactions to methoxsalen occur most commonly when the skin is overexposed to UV light 
or when dosage is excessive. Severe burns may occur if treated skin is accidentally exposed to additional 
UV light. Pruritus occurs in about 10% of patients treated with PUVA therapy utilizing methoxsalen.  
 
8.3 Other adverse dermatologic effects associated with PUVA therapy include skin freckling, 
hypopigmentation, uneven or excessive tanning, dry skin, vesiculation and bullae formation, generalized 
exfoliation, nonspecific rash, urticaria, miliaria, folliculitis, acneiform eruption, aggravation or extension 
of disease, cutaneous tenderness, severe skin pain (lasting 1—2 months), onycholysis, pigmentation of 
the nails, and exacerbation of latent photosensitive dermatoses (e.g., lupus erythematosus).  
 
8.4 Gastrointestinal (GI) Effects  
Nausea is the most common adverse effect of oral methoxsalen, occurring in about 10% of patients. 
Nausea and other adverse GI effects may be minimized by administering 8-MOP with milk or food. 
 
8.5 Central Nervous System (CNS) Effects  
Dizziness and headache can occur with PUVA therapy utilizing methoxsalen.  
 
8.6 Other Adverse Effects  
PUVA therapy may also damage the eyes and may increase the risk of cataract. To reduce these side 
effects eye shields will be used during irradiation and UV protective glasses are required for 24 hours 
after ingestion of 8-MOP.  
 
Cheilitis and transient loss of muscle coordination reportedly occurred in patients receiving oral 
methoxsalen.  
 
Although abnormal liver function test results were reported in a few patients receiving oral methoxsalen, 
this observation has not been confirmed by others and a causal relationship has not been established. 
Edema, malaise, leg cramps, and hypotension occurred with PUVA therapy utilizing methoxsalen.  
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 13 of 29 
9. Premature Termination 
 
9.1 Drop-out 
Drop-out of single study participants may be due to 
• withdrawal of informed consent 
• intolerable adverse events 
• violation of the study protocol 
• emergence of an exclusion criterion  
• emergence of concomitant disease 
• pregnancy 
• any other circumstance that would endanger health of the proband with continued study participation 
 
9.2 Discontinuation of the study 
The investigator may discontinue the study anytime in the interest of the probands if severe adverse 
events or other unforeseen problems occur. 
Ethics Committees concerned and competent authorities should be informed about premature 
discontinuation and its reason within 15 days. 
 
10. Monitoring 
Monitoring will be performed according to the monitoring plan of this study. The investigator will 
cooperate with the monitor and provide unrestricted access to source data and all other study materials. 
The investigator will keep detailed records in the patient charts on study visits, distribution of study 
drugs, test results, concomitant diseases, and adverse events. The monitor will regularly verify entries on 
the CRFs with source data and check compliance with the study protocol and continuous data entry. The 
monitor will handle all data confidentially to ensure integrity and privacy of the study participants. 
 
11. Data protection 
Recording and analysis of personal data within this clinical trial will be performed according to applicable 
data protection laws, provided the study participant has consented to this prior to enrolment. Informed 
consent will include information on data protection as follows: 
 
1. Data collected within this clinical trial will be recorded on case report forms, handled in a strictly 
confidential way. 
 
2. If necessary for evaluation of the clinical trial, authorized personnel of the sponsor, of competent 
authorities and/or Ethics Committees may confidentially review personal data of the study 
participants at the trial site. 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 14 of 29 
3. The study participant will be informed that participation in the clinical trial may be terminated at 
any time without giving a reason and without any consecutive disadvantage. However, due to 
legal requirements, inspection of personal data by authorized persons may be continued in a 
confidential manner. 
 
12. Clinical evaluation and laboratory tests  
 
Patients with histopathologically documented MF and clinical stage IA to II B, who have given informed 
consent and are willing to participate in the study should undergo the following testing and investigation: 
 
12.1. Before treatment start - Pretreatment evaluation (see also Appendix: Table 4: Summary of visits 
and assessments) (Within 28 days before treatment start): 
 
• 
Medical history and clinical examination (if clinically palpable lymph nodes: lymph nodes 
ultrasounds); in case of ultrasonic suspicion of disease-specific lymph node involvement a lymph 
node biopsy and/or excision will be done 
• 
Determination of mSWAT 
• 
Skin biopsies for diagnostic purposes and for determination of cytokine levels as well as T-cell 
receptor rearrangement (TCR-R) 
o All standard study biopsies should be taken from the site of the marker lesion (defined at 
baseline). Biopsies should only be taken from other parts of the body (outside the area of 
the marker lesion) if the response at that site is clinically ambiguous.  
• 
Ophthalmologic examination  
• 
Laboratory tests: Hematology (hemoglobin, WBC with differential and platelet counts), serum 
biochemistry: serum AST (SGOT), ALT (SGPT), alkaline phosphatase, urea, creatinine, and 
glucose 
• 
Antinuclear antibodies (dsDNA, Ro/SSA, La/SSB) 
• 
Blood draw for cytokine, TCR-R and FOXP3 mRNA analysis and Cell free DNA BCT for blood 
tumor cell analysis (see Appendix: Table 5) 
• 
Pregnancy test (for women with childbearing potential) in blood or urine 
• 
Photographic documentation 
• 
DLQI (Dermatology Life Quality Index) 
• 
HADS (Hospital Anxiety and Depression Scale) 
 
 
12.2. During treatment and in the follow-up period:  

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 15 of 29 
Assessments will be done, as described in Appendix Table 4 at specific time points. A biopsy after the 
start of PUVA therapy (e.g. scheduled at week 6 with a gray period of 2 weeks) should be taken on a day 
of PUVA treatment before UVA exposure. 
 
For control purposes blood samples from a maximum of 30 healthy control subjects and 30 samples of 
normal skin available from other studies will be analyzed, together with the samples of this study.  
 
13. Statistics 
Previous studies have shown that MF lesions reappear after a very variable time interval with median 9 to 
15 months, depending on the study [WACKERNAGEL]. PUVA maintenance therapy intends to prolong 
this lesion-free interval and to reduce recurrence rate after discontinuation of the maintenance therapy.  
 
Appendix Figure 2: Overview of treatment effects. All patients get standard PUVA therapy. After 
remission patients are assigned either to controls or to nine months of maintenance therapy. The treatment 
effect is the extension of the median time to recurrence (black double arrow). This comes along with 
lower risk of recurrence (Curve (1) is higher than curve (2)). Some patients suffer from recurrence during 
maintenance therapy, i.e., the tilt in the straight line segment of curve (1) from month 3 to month 12. The 
secondary end point refers to time to recurrence after finishing treatments successfully (dashed curves (3) 
and (4), dashed arrow). Curve (3) gives the survival function after maintenance treatment conditional on 
being free from lesions after therapy. Curve (4) is a shifted version of curve (1) in order to align the 
survival functions for comparison. 
13.1. Study design 
A randomized placebo controlled clinical trial with 3 to 6 months of PUVA therapy as control and 3 to 6 
months PUVA plus 9 months of PUVA maintenance therapy as index therapy. In the Appendix Figure 1 
the time-dependent probability of recurrence (“Survival function”) is given for 4 settings.  
The primary endpoint of the study is the comparison of median time to recurrence after complete 
remission between study arm A and study arm B (comparison of curve (1) vs. curve (2), Appendix: 
Figure 2). A secondary endpoint is the comparison of time from end of treatment to recurrence on 
condition that the patient is in remission at the end of treatment comparing study arm A and B (end of 
treatment in study arm A, month 12 to 15; end of treatment in study arm B, month 3 to month 6). This 
amounts to the comparison between curve (3) and curve (4). After the accrual period patients are 
observed until the closing date of the study for the main statistical outcome analysis. Patients who have 
not experienced recurrence by the closing date are considered as censored. Treatment groups are 
compared by survival analysis (logrank test). 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 16 of 29 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 17 of 29 
13. 2. Sample size calculations and study duration 
Sample sizes were calculated with nQuery Advisor 4.0 software (www.statistical-solutions-
software.com). The assumptions were alpha=0.05, power=0.8, one(two)-sided logrank test and an accrual 
time of 2 years.    
According to an earlier study at the dermatologic clinic the median time to recurrence after PUVA 
therapy was 1 year. An exponential survival function with parameter λ1=0.7 was chosen for controls, 
giving a median time to recurrence of 1 year.  
The alternative hypothesis (i.e. the minimum clinically relevant treatment effect) was chosen to be 
exponential with λ2=0.35 (relative hazard 2, median time to recurrence 2 years) for the primary treatment 
effect. The overall duration of the study (to enrol 55 patients assuming an accrual period of 2 years) until 
closing date for the main statistical outcome analysis was assumed to be four years (accrual phase, 24 
months; initial PUVA treatment of last patient enrolled, 3 months; PUVA maintenance treatment in last 
patient enrolled, 9 months; minimum follow-up period, 12 months). Scenario D1 and D4 refer to these 
assumptions. Independent of the closing date for the main statistical outcome analysis the maximum 
follow-up in an individual patient will be 60 months.  
 
Primary endpoint 
Secondary endpoint 
  
D1 
D2 
D3 
D4 
D5 
D6 
D7 
D8 
  Test significance level 
0.05 
0.05 
0.05 
0.05 
0.05 
0.05 
0.05 
0.05 
  1 or 2 sided test? 
2 
1 
2 
1 
2 
1 
2 
2 
  Length of accrual period 
2 
2 
3 
3 
2 
2 
3 
3 
  Maximum follow up 
3.75 
3.75 
4.75 
4.75 
3 
3 
4 
4 
      Control hazard λ1 
0.7 
0.7 
0.7 
0.7 
0.7 
0.7 
0.7 
0.7 
      Maintenance hazard λ2 
0.35 
0.35 
0.35 
0.35 
0.35 
0.35 
0.35 
0.35 
  Hazard ratio, h=λ1 / λ2 
2 
2 
2 
2 
2 
2 
2 
2 
  Power ( % ) 
80 
80 
80 
80 
72 
73 
74 
76 
  n per group 
47 
37 
44 
35 
47 
37 
44 
35 
  Acrual per year  
(2 Treatments) 
48 
38 
32 
26 
48 
38 
32 
26 
 
For the secondary endpoint (recurrence after 9 months of maintenance therapy vs. recurrence after 
standard therapy only) essentially the same scenario was assumed: exponential survival, hazard ratio 2. 
Only the length of follow up war shortened by 0.75 years. In this regard not power but sample size was 
fixed and the power was variable. Scenario D5 to D8 relate to these assumptions.  
Finally scenario D2 was chosen. 37 patients per group are required (41 patients if accounting for 10% loss 
to drop-out, non-compliance and/or follow-up). 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 18 of 29 
13.3. Randomization procedure 
After a maximum of 24 weeks (48 PUVA treatments) patients without complete remission will 
discontinue active study participation but they will be followed up in an observatory arm. Patients with 
complete remission after 12 weeks (24 PUVA treatments), 16 weeks (32 PUVA treatments), 20 weeks 
(40 PUVA treatments) or maximum of 24 weeks (48 PUVA treatments) will be randomized by a 
computerized randomization service to receive either PUVA-maintenance therapy (*Arm A*) or no 
maintenance therapy (*Arm B*) (Appendix: Figure 1). Randomization will be done using Randomizer, 
Medical University of Graz, Austria (https://www.randomizer.at/random). 
 
14. ETHICAL AND LEGAL ASPECTS 
 
 
Acknowledgement / approval of the study 
 
Approval from the ethics committee (EC) must be obtained before starting the study.  
The clinical trial shall be performed in full compliance with the legal regulations according to the Drug Law 
(AMG - Arzneimittelgesetz) of the Republic of Austria. 
An application must also be submitted to the Austrian Competent Authorities (CA) (Bundesamt für Sicherheit 
im Gesundheitswesen (BASG) represented by the Agency for Health and Food Safety (AGES PharmMed) and 
registered to the European Clinical Trial Database (EudraCT) using the required forms. The timelines for 
(silent) approval set by national law must be followed before starting the study. 
 
Changes in the Conduct of the Study 
 
 
Protocol amendments 
Proposed amendments must be submitted to the appropriate CA and ECs. Substantial amendments may be 
implemented only after CA/EC approval has been obtained. Amendments that are intended to eliminate an 
apparent immediate hazard to subjects may be implemented prior to receiving CA/EC approval. However, in 
this case, approval must be obtained as soon as possible after implementation. 
 
Study Termination 
If the sponsor or the investigator decides to terminate the study before it is completed, they will notify each 
other in writing stating the reasons of early termination. In terminating the study, the sponsor and the 
investigator will ensure the adequate consideration is given to the protection of the subject interests. The 
investigator, sponsor or (designated CRO on behalf of the sponsor) will notify the relevant CA and EC. 
Documentation will be filed in the Trial Master and Investigator Files.     
 
Clinical Study Report (CSR) 
Within one year after the final completion of the study, a full CSR will be prepared by the sponsor and 
submitted to the EC and the competent authority. 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 19 of 29 
 
15. SIGNATURES 
15.1 Sponsor 
Herewith I confirm that the clinical trial will be performed in accordance with ICH-GCP, the Declaration of 
Helsinki, local legislation and the present study protocol. 
 
 
 
______________________________ 
______________________________ 
Name  
 
 
Date 
 
15.2 Investigator 
Herewith I confirm to have read and to comply with the present study protocol and to ensure that enrolled 
patients will be followed and treated according to the study protocol. 
 
 
 
______________________________ 
______________________________ 
Name  
 
 
Date 
 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 20 of 29 
16. References 
Burg G,  Häffner A, Böni R, et al. New perspectives in experimental and clinical research for cutaneous T 
cell lymphomas. Recent results Cancer Res 1995; 139: 225-237. 
Diederen PV, van Weelden H., Sanders CJ, et al : Narrowband UVB and psoralen-UVA in the treatment 
of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003; 48: 215-19. 
Dummer R, Assaf C, Bagot M. Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what? 
Eur J Cancer 2007; 43: 2321-2329. 
Gilchrest BA, Parrish JA, Tanenbaum L, et al. Oral methoxsalen photochemotherapy of mycosis 
fungoides. Cancer 1976; 38: 683-689. 
 
Hönigsmann H, Brenner W., Rauschmeier W. et al. Photochemotherapy for cutaneous T cell lymphoma. 
A follow-up study. J Am Acad Dermatol 1984; 10: 238-45. 
Hönigsmann H, Tanew A. Photo(chemo)therapy for cutaneous T-cell lymphoma; pp135-149. In: Jean 
Krutmann et al. (Eds.), Dermatological Phototherapy and Photodiagnostic Methods. DOI: 10.1007/978-
3-540-36693-5, © Springer 2009 
Hwang ST, Janik JE, Jaffe ES, et al.  Mycosis fungoides and Sezary syndrome. Lancet 2008; 15: 945-57. 
Olsen E, Vonderheid E, Pimpinelli N. et al. Revisions to the staging and classification of mycosis 
fungoides and Sézary syndrome: a proposal of the International Society for CutaneousLymphomas 
(ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment 
of Cancer (EORTC). Blood 2007; 110: 1713-1722. (a) 
 
Olsen EA, Kim YH, Kuzel et al. Phase IIb multicenter trial of vorinostat in patients with persistent, 
progressive, or treatment refractory cutaneousT-cell lymphoma. J Clin Oncol 2007; 25:3109-3115. (b) 
Pothiawala S, Baldwin BT, Cherpelis BS, et al. The role of maintenance phototherapy in cutaneous T-cell 
lymphoma. J Drugs Dermatol 2010; 9: 800-803. 
Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-
cell lymphoma who achieved complete remission with psoralen plus UVA-monotherapy. Arch Dermatol 
2005; 141: 305-311. 
Roenigk HH, Jr. Photochemotherapy for mycosis fungoides. Arch Dermatol 1977; 113: 1047-51. 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 21 of 29 
Sanchez  M, Gonzalez T, Gaitan M, et al. Is PUVA maintenance therapy necessary in patients with early-
stage mycosis fungoides? Evaluation of a treatment guideline over a 28-month follow-up. Int J Dermatol 
2011  doi: 10.1111/j.1365-4632.2010.04833.x. 
Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis fungoides–type 
cutaneous T-cell lymphomas. Arch Dermatol. 2002;138:42–48. 
Trautinger F.  Phototherapy of mycosis fungoides. Photodermatol Photoimmunol Photomed. 2011; 27:68-
74. 
Wackernagel  A, Hofer A, Kerl H, Wolf P. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus 
ultraviolet A therapy in patients with mycosis fungoides.  Br J Dermatol 2006; 154: 519-523. 
Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood  
2005; 105: 3768 - 85. 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 22 of 29 
 
Appendix (Tables and Figures) 
 
Table 1: 
 
TNM Cutaneous Lymphoma  
 
TNM classification for mycosis fungoides (including “B” system for CTCL to incorporate Sezary 
syndrome); according to the ISCL/EORTC revision to the staging of mycosis fungoides and Sezary 
syndrome [OLSEN (a)] 
 
Skin  
 
T1 Limited patches/plaques (<10% of total skin surface)  
T2 Extensive patches/plaques (>10% of total skin surface)  
T3 Tumours  
T4 Erythroderma  
 
Nodes  
 
N0 No clinical lymphadenopathy  
N1 Clinically enlarged lymph nodes but histologically uninvolved  
N2 Lymph nodes not enlarged but histologically involved  
N3 Clinically enlarged lymph nodes and histologically involved  
 
Visceral  
 
M0 No visceral involvement  
M1 Visceral involvement  
 
Blood  
 
B0 No peripheral blood Sezary cells (<5%)  
B1 Peripheral blood Sezary cells (>5% of total lymphocyte count)  
B2 High blood tumor burden  
 
 
Clinical Staging system for CTCL (mycosis fungoides)  
 
Clinical Stage T N M B 
 
IA T1 N0 M0 B01 
IB T2 N0 M0 B01 
IIA T1-2 N1 M0 B01 
IIB T3 N0-1 M0 B01 
III T4 N0-1 M0 B01 
IVA T1-4 N2-3 M0 B0-2 
IVB T1-4 N0-3 M1 B0-2 
 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 23 of 29 
Table 2: 
 
Karnofsky scale for performance status  
 
Index Performance scale  
100 Normal; no complaints.  
90 Able to carry on normal activities; minor signs or symptoms of  
disease.  
80 Normal activity with effort.  
70 Cares for one self. Unable to carry on normal activity or to do  
active work.  
60 Ambulatory. Requires some assistance in activities of daily living  
and self care.  
50 Requires considerable assistance of frequent medical care.  
40 Disabled; requires special care and assistance.  
30 Severely disabled; hospitalization indicated though death not  
imminent.  
20 Very sick; hospitalization and active supportive treatment.  
10 Moribund  
0 Dead  
 
 
 
 
 
 
 
 
 
 
 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 24 of 29 
Table 3: 
Modified Severity Weighted Assessment Tool (mSWAT) 
 
 
 
 
 
mSWAT score  =  Summation of Subtotal lesion BSA x Weighting factor products 
 
 
 
above  (Patch + Plaque + Tumor) 
 
 
Percentage of diseased area 
Body region 
(%BSA) 
Patch 
Plaque 
Tumor 
 
Head (7 %) 
 
 
 
 
Neck (2%) 
 
 
 
 
Anterior trunk 
(13%) 
 
 
 
Arms (8%) 
 
 
 
 
Forearms 
(6%) 
 
 
 
Hands (5%) 
 
 
 
 
Posterior trunk 
(13%) 
 
 
 
Buttocks (5%) 
 
 
 
 
Thighs (19%) 
 
 
 
 
Legs (14%) 
 
 
 
 
Feet (7%) 
 
 
 
Groin (1%) 
 
 
 
 
Subtotal of 
lesion BSA 
 
 
 
Weighting 
factor 
1 
2 
4 
Subtotal lesion 
BSA x 
weighting 
factor 
 
 
 
mSWAT score = 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 25 of 29 
Table3: 
 
 
 
 
BODY CHART 
 
 
 
 
 
 
Erforderliche Parameter fehlen oder sind falsch. 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 26 of 29 
Table 4: Summary of visits and assessments 
 
 
Within 4 
weeks f 
Treatment 
 
Optional (4 opt.) g 
 
End of PUVA  
maintenance 
Observatory 
Patient h 
Follow  
up p 
Visit No. 
1 
2 
3 
4a 
4b 
4c 
4d 
5 
6 
7 
8 
8 
 
Weeks 
-4 to 0 
+3 j 
+6 k 
+12 
+16 
+20 
+24  
+16, +20,  
+24 or +28 l  
+24, +28,  
+32 or +36 m 
+36, +40,  
+44 or +48 n 
+48, +52,  
+56 or +60 o 
 
 
ASSESSMENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical History 
x 
 
 
 
 
 
 
 
 
 
 
x 
 
Concomitant Medication 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Adverse Event Report 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
x 
Clinical examination 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
mSWAT + Body Chart  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Hematology 
x 
x 
x 
x 
(x) 
(x) 
x 
 
x 
x 
x 
 
 
Serum biochemistry 
x 
x 
x 
x 
(x) 
(x) 
x 
 
x 
x 
x 
 
 
Antinuclear antibody + Ro-La 
x 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine analysis 
x 
 
x 
x 
(x) 
(x) 
x 
 
x 
 
x 
 
 
Disease monitoring 
laboratory investigations 
including TCR-R+FOXP3 
mRNA a 
x 
 
x 
x 
(x) 
(x) 
x 
 
x 
 
x 
 
 
FACS analysis b  
x 
 
x 
x 
(x) 
(x) 
x 
 
x 
 
x 
 
 
Treg functional assay b 
x 
 
x 
x 
(x) 
(x) 
x 
 
x 
 
x 
 
 
CELL free DNA only for Graz 
x 
 
x 
x 
(x) 
(x) 
x 
 
x 
 
x 
 
 
Skin biopsy 
x 
 
x 
(x) q 
(x) q 
(x) q 
x 
 
optional 
 
optional 
 
optional 
Ophthalmologic examination 
x 
 
 
 
 
 
 
 
 
 
 
 
 
DLQI c 
x 
 
 
x 
 
 
x 
 
x 
x 
x 
 
x 
HADS d 
x 
 
 
x 
 
 
x 
 
x 
x 
x 
 
x 
Photographic assessment e 
x 
 
x 
x 
optional 
optional 
x 
optional 
optional 
optional 
optional 
 
optional 
Pregnancy test 
(ß-HCG blood or urine test 
strip) (monthly) i 
x 
x 
x 
x 
x 
 
x 
 
(x)  
(x) 
 
 
 
Randomization g 
 
 
 
x g 
x g 
x g 
x g 
 
 
 
 
 
 
 
a TCR-R: T-cell receptor rearrangement and FOXP3 mRNA 
b To analyse on site if procedure is available 
c DLQI: Dermatology Life Quality Index 
d HADS: Hospital Anxiety and Depression Scale 
e Photographic assessment: optional in case of recurrence 
f Before treatment start (within 4 weeks) 
g Randomization: time of randomization at V4a, V4b, V4c or V4d if 
complete remission 
h For patients who were not randomized in Group A or B 
i Pregnancy test: has to be taken once a month till Randomization and after Randomization in 
Study Arm A 
j 3 weeks after treatment start 
k 6 weeks after treatment start 
l Time of visits: depends on the numbers of optional visits 
m 12 weeks after start of maintenance therapy 
n 24 weeks after start of maintenance therapy 
o 36 weeks after start of maintenance therapy  
p every three months in the first year, every 6 months in the second year and once a year in years 3 to 5 after PUVA maintenance therapy 
q Skin biopsy: in the case of complete clinical response at the time of randomization  

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 27 of 29 
Table 5: Cytokines and chemokines will be analyzed, including: 
 
IL-1a, IL-1b, IL-4, IL-6, IL-9, IL-10, IL-13, IL-12p35, IL-12p40, IL-12p70, IL-17A, IL-17F, IL-23, IL-23p19, TGF-β1, IFN-γ, TNF-α, G-CSF, GM-CSF, MCP-1, 
RANTES, KC, IP-10, MIP-1a and others 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 28 of 29 
Figure 1: 
 

M-PUVA 2012 Protocol 
 
M-PUVA 2012, Protocol, Version 2.1, February 23, 2018                                                       Page 29 of 29 
 
Figure 2:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
1
2
3
4
0.0
0.5
1.0
Recurrence free
Years
(1) Maint. th.
(2) Controls
(3) Maint. th., completed
(4) Controls, shifted
Therapy
maint.
std.
Shift
Delayed recurrence
Treatment effect